Tools for Practice Outils pour la pratique

#36 In atrial fibrillation: rate versus rhythm and how slow do you go?

For patients with persistent atrial fibrillation (A Fib), how does medically attempting to restore/maintain sinus rhythm compare to rate control (and what should be the target heart rate)?

Patients with persistent Afib are more likely to benefit from rate control than rhythm control. Targeting resting heart rate to <80 does not appear necessary. Regardless of the treatment strategy, anti-thrombotic therapy is central to management.

CFPCLearn Logo

Reading Tools for Practice Article can earn you MainPro+ Credits

La lecture d'articles d'outils de pratique peut vous permettre de gagner des crédits MainPro+

Join Now S’inscrire maintenant

Already a CFPCLearn Member? Log in

Déjà abonné à CMFCApprendre? Ouvrir une session

Rate versus rhythm: Two latest meta-analyses1,2 of 10-13 Randomized Controlled Trials (RCTs) comparing pharmacological rate versus rhythm control in 7,867 patients: 
  • Statistically significantly fewer hospitalizations:1 50.8% versus 58.3%, Number Needed to Treat (NNT)=14. 
  • No difference in individual composite of embolic events, or individual outcomes of death, stroke or systemic embolism, worsening heart failure, or bleeding.1,2 
  • Similar quality of life.2 
  • Less likely to be in sinus rhythm (example from largest RCT:3 35% versus 63%). 
Strict versus lenient rateRCT4 (614 patients, mean age 68 years, 66% male, 61% CHADS score 0-1, followed up to three years) compared strict rate control (resting heart rate target <80) or lenient rate control (resting heart rate target <110). Lenient rate control was not inferior to strict rate control in: 
  • Composite outcome of cardiovascular, bleed, and hospitalization (12.9% versus 14.9% [hazard ratio 0.84 (90% CI 0.58 to 1.21)].  
  • Although historically it was thought attempting to restore sinus rhythm was advantageous, medications used to establish and maintain sinus rhythm have several risks.   
  • Even in patients with coexistent congestive heart failure and AFib, mortality and morbidity outcomes did not differ between rate and rhythm groups.5 
  • Canadian guidelines recommend:6 
    • Rate control for most patients; 
    • Select patients may benefit from rhythm control, e.g. highly symptomatic, quality of life impairment, multiple recurrences, arrhythmia-induced cardiomyopathy. 
  • Regardless of treatment strategy, antithrombotic therapy is central to AFib management.6 
updated jan 19 2018 by ricky

Latest Tools for Practice
Derniers outils pour la pratique

#365 Shrooms for Glooms: Evidence for psilocybin for depression

What are the benefits and harms of psilocybin for treatment-resistant/recurrent depression?
Read Lire 0.25 credits available Crédits disponibles

#364 Facing the Evidence in Acne, Part II: Oral Antibiotics

How effective are oral antibiotics in treating acne of at least mild-moderate severity?
Read Lire 0.25 credits available Crédits disponibles

#363 Making a difference in indifference? Medications for apathy in dementia

In patients with dementia, how safe and effective are stimulants, antidepressants, and antipsychotics for treating apathy?
Read Lire 0.25 credits available Crédits disponibles

This content is certified for MainPro+ Credits, log in to access

Ce contenu est certifié pour les crédits MainPro+, Ouvrir une session

  • G. Michael Allan MD CCFP
  • Michael R Kolber MD CCFP MSc

1. Chatterjee S, Sardar P, Lichstein E, et al. PACE. 2013; 36:122-33.

2. Al-Khatib SM, Allen LaPointe NM, Chatterjee R, et al. Ann Intern Med. 2014; 160:760-73.

3. AFFIRM Investigators. N Engl J Med. 2002; 23:1825-33.

4. Van Gelder IC, Groenveld HF, Crijns HJ, et al. N Engl J Med. 2010; 362:1363-73.

5. Roy D, Talajic M, Nattel S, et al. N Engl J Med. 2008; 358:2667-77.

6. Verma A, Cairns JA, Mitchell LB, et al. Can J Cardiol. 2014; 30:1114-30.

Authors do not have any conflicts of interest to declare.

Les auteurs n’ont aucun conflit d’intérêts à déclarer.